ClarivateTM Analytics released the 2021 update of its Journal Citation Reports©, including the much anticipated 2020 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2020 impact factor of 25.083, up from the 2019 score of 20.582.
Geneva, Switzerland, 30 June 2021 – The ranking reveals that the Journal of Hepatology continues to surge ahead with an impressive 21.86% increase in one year and a total increase of almost 100% in the past four years. To date, the 2020 score is the highest the Journal of Hepatology has achieved.
“The Journal of Hepatology has outdone itself once again, being awarded its highest ever impact factor of 25.083! The sheer leap of more than 20% from last year’s impact factor to this year’s speaks for itself. On behalf of the EASL Governing Board, I extend hearty congratulations to the editorial team, its board, the Journal office, the tireless peer reviewers, and the highly innovative authors. Because this journal strives constantly to refine quality and continue innovation, it attracts some of the most important papers in the literature. These publications carry true impact on research and clinical practice. Let me further express gratitude to Prof. Paolo Angeli and his team, and the editors-in-chief, and editorial boards, current and past, who have driven this excellence over the years, making this an established top-tier journal,”
said Prof. Thomas Berg, Secretary General of EASL.
“The Journal has further increased its impact factor in the last year, confirming its position at the top of the Journal rankings in the field of Hepatology and Gastroenterology. I always thought that if achieving this position was very difficult, maintaining it would be even more difficult. Thus, it is my great duty and pleasure to thank all of those who contributed and who are still contributing to this great result, starting with the senior and associate editors and all the reviewers. All of them have performed outstanding work to provide the scientific community with very high-quality articles in the field of basic as well as clinical hepatology. I want to give special thanks to the members of the Editorial Office for their great dedication and professionalism to a task that has been and remains challenging in these times. Our aim for the future is to continue to improve our service to the community. We will try to further improve the quality of papers that we publish and we will pay even more careful attention to developing a widespread and active interaction with all the members of our community: scientists, physicians, patients, caregivers, and decision-makers in healthcare, through an optimised use of social media. This is the mandate we have received from EASL, the Home of Hepatology™, and we will continue to pursue this to the best of our ability,”
said Prof. Paolo Angeli, Editor-in-Chief of the Journal of Hepatology.
The record high score, together with similar increases in other metrics, reaffirms the continued commitment of EASL, to provide the scientific community with a high-quality publication that delivers impactful content in liver research.
An impact factor is a measure of a journal’s significance in an academic field. It considers the frequency with which the average article in a journal is cited in a given year. This data helps indicate a journal’s relative importance when compared to other publications in the same field. The Journal of Hepatology publishes 12 issues a year and covers a wide variety of topics in clinical and basic research within the field.
About the Journal of Hepatology
The Journal of Hepatology is the official journal of the European Association for the Study of the Liver (EASL). It publishes original papers, reviews, case reports, and letters to the Editor concerned with clinical and basic research in the field of hepatology. It is a monthly, English language, peer-reviewed journal. First published in 1985 as the official journal of EASL, it provides an international forum for the publication of original articles, reviews and letters to the Editor describing basic laboratory, translational, and clinical investigations in hepatology. All articles undergo a rigorous peer review and are selected based on the originality of the findings, the superior quality of the work described, and the clarity of presentation. Visit the website of the Journal of Hepatology.
About The European Association for the Study of the Liver (EASL) – The Home of Hepatology
EASL, the European Association for the Study of the Liver, founded in 1966, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology. As of 2021, EASL serves more than 4,200 members.
EASL engages globally with all stakeholders in the field of hepatology, worldwide. Our aim is to spread knowledge and expertise in best practices and the latest scientific breakthroughs in this field. We advocate for the benefit of patients and advise European and national health authorities. EASL runs topical conferences, schools, and related educational meetings. Our journals, the Journal of Hepatology and JHEP Reports, provide an international forum for the publication of original articles, reviews, and letters to the Editor, describing the latest science in hepatology. Our eLearning hub, EASL Campus, offers more than 4,100 resources on hepatology and liver research.
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect, and commercialise their inventions, using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.